Trial · NCT03487263
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence of treatment-emergent adverse events (safety, tolerability) | one month | Number of participants with treatment-emergent adverse events (safety, tolerability) classified by MedDRA |
| Secondary | Treatment-related change in ALSFRS-R functional scale | one month | Treatment-related change in Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) \[0 (worst) to 48 (best)\] |
| Secondary | Respiratory function | one month | Treatment-related change in percent normal Forced Vital Capacity \[0% (worst) to 100% (best)\] |
| Secondary | Muscle function | one month | Treatment-related change in percent normal Sniff Nasal Pressure \[0% (worst) to 100% (best)\] |
| Secondary | Quality of life measured by ALSSQOL | one month | Treatment-related change in Amyotrophic Lateral Sclerosis Specific Quality of Life - Revised (ALSSQOL-R) \[0 (worst) to 460 (best)\] |
| Secondary | Patient-reported outcome | one month | Treatment-related change Edinburgh Cognitive and Behavioural Assessment Score (ECAS) \[0 (worst) to 136 (best)\] |
| Secondary | Maximum Plasma Concentration (Cmax) | one month | Maximum serum IC14 concentration (micrograms per milliliter) |
| Secondary | Area Under the Curve (AUC) | one month | Area Under the Curve for serum IC14 (microgram x hr/mL) |
| Secondary | Monocyte CD14 Receptor Occupancy | one month | Treatment-related change in percent monocyte CD14 receptor occupancy as a pharmacodynamic marker |
| Secondary | Urinary p75 neurotrophin receptor (biomarker) | one month | Treatment-related change in urinary concentration of urinary p75 neurotrophin receptor (NTR) (nanograms per milligram creatinine) |
| Secondary | Neurofilament (biomarker) | one month | Treatment-related change in concentration of neurofilament (picograms per milliliter) |
| Secondary | Anti-drug antibodies | one month | Development of human anti-monoclonal antibodies following treatment |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03487263/registered